

**REMARKS**

Applicants wish to express their appreciation to Examiner Zara for the courtesy of the telephonic interview of September 16, 2002 in which a Response to the outstanding Restriction Requirement was discussed. In this telephonic interview, Applicants specifically requested that instead of responding to the outstanding Restriction Requirement by electing no more than 10 sequences of claim 3, Applicants be permitted to amend claims 1 and 14 to be directed toward SEQ ID NO:243, as noted herein. Examiner Zara indicated that such an amendment, limiting the claims to a single searchable target sequence SEQ ID NO:243, would likely be considered responsive to the present Restriction Requirement.

Following entry of this response, claims 1-2 and 4-44 are pending. Applicants wish to point out to the Examiner that Applicants did not cancel claim 44, which claim should still be considered pending in this application. Claim 3 has been canceled, without prejudice. Applicants reserve the right to prosecute the invention of claim 3 in a divisional application filed during the pendency of the present application. Claims 1 and 14 are amended to incorporate the target SEQ ID NO:243.

Applicants have enclosed as Appendix A, a version of the amended claims with markings to show changes made. Applicants have also enclosed as Appendix B, a clean copy of the pending claims. No new matter is added by this amendment.

The Director is hereby authorized to charge any deficiency in any fees due with the filing of this paper or credit any overpayment in any fees to our Deposit Account Number 08-3040.

Respectfully submitted,

HOWSON AND HOWSON  
Attorneys for Applicants

By Mary E. Bak  
Mary E. Bak  
Registration No. 31,215  
Spring House Corporate Center  
Box 457  
Spring House, PA 19477  
(215) 540-9200

## Appendix A

### Version with Markings to Show Changes Made

1(Amended). A compound 8 to 50 nucleobases in length targeted to a nucleic acid molecule encoding PTP1B SEQ ID NO: 243, wherein said compound specifically hybridizes with and inhibits the expression of PTP1B.

~~3(Canceled).—The compound of claim 2 wherein the antisense oligonucleotide has a sequence comprising SEQ ID NO: 18, 19, 20, 21, 22, 23, 24, 26, 27, 29, 30, 32, 33, 35, 36, 38, 39, 40, 42, 45, 46, 47, 48, 49, 50, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 69, 70, 72, 73, 75, 78, 79, 80, 81, 83, 84, 86, 87, 89, 90, 92, 93, 94, 95, 96, 97, 99, 100, 101, 102, 103, 104, 106, 107, 108, 109, 110, 112, 113, 114, 115, 117, 120, 121, 122, 123, 124, 126, 127, 128, 130, 131, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 144, 145, 146, 147, 148, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 168, 169, 170, 171, 172, 173, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 191, 193, 195, 196, 198, 201, 202, 204, 205, 206, 211, 215, 217, 219, 223, 225, 226, 228, 229, 230, 232, 233, 235, 236, 237, 239, 240, 244, 245, 247, 248, 249, 250, 251, 252, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 267, 268, 269, 271, 275, 276, 277, 278, 279, 281, 282, 283, 288, 290, 291, 292, 294, 296, 297, 298, 299, 300, 302, 303, 307, 310, 311, 313, 315, 317, 318, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 337, 340, 341, 342, 343, 344, 345, 347, 349, 350, 351, 352, 353, 354, 355, 356, 357, 358, 360, 361, 362, 363, 364, 365, 366, 368, 369, 371, 372, 373, 374, 375, 377, 378, 380, 381, 384, 385, 386, 387, 388, or 389.~~

14(Amended). A compound 8 to 50 nucleobases in length which specifically hybridizes with at least an 8-nucleobase portion of an active site on a nucleic acid molecule encoding PTP1B SEQ ID NO: 243.